Patents by Inventor Margaret Ann Marshall

Margaret Ann Marshall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANCER TREATMENT
    Publication number: 20160060343
    Abstract: The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subject's response to a cancer treatment.
    Type: Application
    Filed: July 22, 2015
    Publication date: March 3, 2016
    Inventors: Bo Huang, Margaret Ann Marshall
  • Cancer treatment
    Patent number: 9119839
    Abstract: The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subject's response to a cancer treatment.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: September 1, 2015
    Assignee: Pfizer Inc.
    Inventors: Bo Huang, Margaret Ann Marshall
  • Cancer treatment
    Patent number: 8435516
    Abstract: The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subjects response to a cancer treatment.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: May 7, 2013
    Assignee: Pfizer Inc.
    Inventors: Bo Huang, Margaret Ann Marshall
  • CANCER TREATMENT
    Publication number: 20120213793
    Abstract: The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subjects response to a cancer treatment.
    Type: Application
    Filed: October 4, 2010
    Publication date: August 23, 2012
    Applicant: Pfizer Inc.
    Inventors: Bo Huang, Margaret Ann Marshall